The Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussion about drug pricing and accessibility. The existing regulatory framework aims to provide affordable medicines while supporting the pharmaceutical industry. Ensuring pricing transparency and targeted interventions can help address excessive margins in the supply chain. The ultimate goal remains to enhance patients' access to quality medicines at reasonable prices.